Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 Omicron Variant (XBB Lineage) (Spike RBD (XBB))
- Target
- Spike RBD (XBB)
- Molecular classification
- Glycoprotein, Viral protein, Receptor binding domain
01
Overview
The Spike Glycoprotein S1 Receptor Binding Domain (RBD) of the SARS-CoV-2 Omicron XBB lineage is a critical viral protein responsible for binding to the human ACE2 receptor, initiating viral entry into host cells. It contains key mutations that enhance immune evasion and alter ACE2 binding affinity, impacting the effectiveness of existing vaccines and therapeutics. The XBB RBD is a major target for neutralizing antibodies and vaccine development efforts.
- Other names
- SARS-CoV-2 Spike RBD XBBOmicron XBB Spike RBDXBB RBDSpike protein RBD (XBB lineage)
02
Mechanism of action
Binding to ACE2 receptor on host cells, blocking viral entry; Neutralization by antibodies preventing ACE2 interaction
03
Biological functions
Receptor bindingViral entryImmune evasionACE2 binding
04
Disease associations
InfectionCOVID-19Viral pathogenesis
05
Safety considerations
Potential for antibody-dependent enhancement (ADE)Evolving mutations leading to immune escapeReduced efficacy of existing vaccines and therapeutics
06
Interacting drugs
Monoclonal antibodies (therapeutic)
1 more in the full profile.
07
Biomarkers
RBD mutations (e.g., L455F, F456L) for variant identificationACE2 binding affinity for infectivity assessmentNeutralizing antibody titers against XBB RBD for assessing immunity
Beyond the preview
Go deeper on Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 Omicron Variant (XBB Lineage) (Spike RBD (XBB)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 Omicron Variant (XBB Lineage) (Spike RBD (XBB)).